Study confirms real-world efficacy of TARGIT-IORT for early-stage breast cancer

Targeted intraoperative radiotherapy (TARGIT-IORT) provides effective long-term cancer control and survival outcomes for early-stage breast cancer, consistent with results from the TARGIT-A trial, according to a study that confirms the technique can be successfully implemented in real-world clinical settings with minimal toxicity.

The study analyzed 814 patients treated with TARGIT-IORT during lumpectomy, following the risk-adapted TARGIT-A protocol.

The median follow-up period was 72 months. Among participants, 60.3% received TARGIT-IORT as a standalone partial breast irradiation (PBI) treatment, while 39.7% had additional external beam radiotherapy (EBRT). The 5-year in-breast tumor recurrence (IBTR) rate was comparable between the overall cohort (1.6%) and those receiving only IORT (2.5%). Overall survival and breast cancer-related survival rates exceeded 95%. Breast preservation was possible in 21% of patients with recurrence, and severe radiotherapy toxicity (Grade >2) was observed in only 0.9% of cases.

Reference
Vinante L, Vaidya JS, Caroli A, et al. Real world clinical outcomes from targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer: data from a large cohort at a national cancer institute. Front Oncol. 2024;14:1424630. doi: 10.3389/fonc.2024.1424630. PMID: 39421443; PMCID: PMC11484062.